Moderna forecasts lower sales next year, shares near four-year low

Sep 12, 2024 · Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast …

$2
OFF

Moderna Forecasts Lower Sales Next Year, Shares Near Four-Year …

2 weeks from now

Sep 12, 2024 · The company expects sales between $2.5 billion and $3.5 billion in 2025, below analysts' forecast of $3.74 billion, according to LSEG data.

usnews.com

$1
OFF

Moderna Cuts 2025 Sales Forecast By $1 Bln On Weak Vaccine …

2 weeks from now

2 days ago · Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending …

reuters.com

94%
OFF

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?

2 weeks from now

1 day ago · Moderna stock peaked at 497.49 in August 2021, at the height of the Covid pandemic. Since then, the stock has fallen precipitously, down 94% over the past four years. Is Moderna …

investors.com

$2
OFF

Moderna Forecasts Lower Sales Next Year, Shares Near Four-year Low

2 weeks from now

Sep 12, 2024 · The company expects sales between $2.5 billion and $3.5 billion in 2025, below analysts' forecast of $3.74 billion, according to LSEG data. The midpoint was also below the …

investing.com

17%
OFF

Moderna Stock Plunges Nearly 17% After Company Lowers 2025 …

2 weeks from now

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.

msn.com

20%
OFF

Moderna Shares Fall Amid Lower Sales Outlook For RSV, COVID Shots

2 weeks from now

Aug 1, 2024 · Shares of Moderna fell nearly 20% on Thursday after the company lowered its 2024 financial forecasts amid slowing sales and growing competition for its vaccines. Alongside its …

biopharmadive.com

17%
OFF

Vaccine Maker Moderna Sees Sales Fall Next Year, Shares Fall 17% To ...

2 weeks from now

Sep 12, 2024 · Moderna on Thursday pushed back its breakeven target by two years after it slowed development timelines for several key products and forecast 2025 sales below …

businessinvestopedia.com

$18
OFF

Moderna's MRNA Technology Looks Undervalued Despite Lower …

2 weeks from now

1 day ago · Moderna's massive covid vaccine sales and prepayments left it with $18.2 billion in cash at the end of 2022, but that balance is steadily shrinking due to previous share …

morningstar.com

FAQs about Moderna forecasts lower sales next year, shares near four-year low Coupon?

Why did Moderna shares drop 22 per cent on Monday?

Moderna shares dropped as much as 22 per cent on Monday after the US biotech group’s sales forecasts disappointed investors. The Boston-based company projected sales this year of $1.5bn-$2.5bn, down from a previous forecast of $2.5bn-$3.5bn and lower than some analyst estimates for $2.4bn-$2.9bn. ...

Why did Moderna lower its 2025 sales guidance?

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio. Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year. ...

Why did Moderna stock fall 22%?

By Connor Hart Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.07 in late morning trading Monday. ...

How much will Moderna sell in 2026?

REUTERS/Brian Snyder/File Photo By Patrick Wingrove (Reuters) - Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028. ...

Why did Moderna cut its 2025 forecast?

Moderna (MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects $1.5 to $2 billion in revenue for 2025. ...

Why did Moderna's stock fall 22% in August 2021?

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.07 in late morning trading Monday. The stock has tumbled 93% from its five-year high of $456.76 in August 2021. ...